Alto Neuroscience Reports $27.6 Million Net Loss and Increased R&D Expenses in Latest 10-Q

Alto Neuroscience, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2026. The company recorded a net loss of $27.6 million for the quarter, compared to a loss of $17.7 million in the same period last year, reflecting an increase in operating expenses driven primarily by research and development costs. Total operating expenses for the quarter reached $29.1 million, up from $18.7 million in the prior year, with research and development expenses alone rising to $22.1 million from $13.1 million. The increase in expenses is attributed to the advancement of clinical trials, particularly for the ALTO-207 program, which the company acquired in May 2025.

In terms of liquidity, Alto reported cash, cash equivalents, and restricted cash totaling $243.7 million as of June 30, 2026, a notable increase from $176.5 million at the end of 2025. This increase was bolstered by a successful underwritten registered direct offering in July 2026, which generated approximately $94.6 million in net proceeds. The company also raised $114.8 million in a private placement in March 2026, further enhancing its financial position. Alto's accumulated deficit now stands at approximately $255.5 million, reflecting its ongoing investment in product development without generating revenue from product sales.

Operationally, Alto has made strides in its clinical pipeline, which includes seven clinical-stage assets targeting high-need therapeutic areas such as major depressive disorder and bipolar depression. The company initiated a Phase 2b trial for ALTO-207 in April 2026 and plans to advance additional trials for other product candidates. The increase in research and development expenses is largely due to costs associated with these clinical activities, including manufacturing and personnel-related expenses. The company has also expanded its workforce, contributing to higher general and administrative costs, which rose to $7.0 million from $5.6 million year-over-year.

Looking ahead, Alto anticipates continued operating losses as it progresses through clinical development phases for its product candidates. The company has indicated that it will require substantial additional funding to support its operations and development activities. While it believes that its current cash reserves, along with anticipated proceeds from the Convertible Grant Agreement with Wellcome, will be sufficient to fund operations for at least the next 12 months, it acknowledges the inherent risks and uncertainties in achieving its clinical and financial objectives. The company remains focused on advancing its pipeline and securing the necessary capital to support its growth strategy.